Phase I trial of pentosan polysulfate

S. M. Swain, B. Parker, A. Wellstein, Marc E Lippman, C. Steakley, R. DeLap

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Pentosan polysulfate is a semisynthetic pentasaccharide heparinoid derived from beechwood shavings. A total of nineteen patients with various adult solid tumors were treated with three dose levels (15, 22.5, and 30 mg/m2/dose) of subcutaneous pentosan polysulfate every 6 hours. The dose limiting toxicities were thrombocytopenia and elevated transaminases at the dose of 30 mg/m2 every 6 hours. The recommended starting dose for phase II trials is 22.5 mg/m2 given every 6 hours. There was an increase in anticoagulant activity as measured by activated partial thromboplastin time (aPTT) at the dose of 22.5 mg/m2 every 6 hours in most patients. There were no objective responses and three patients had stable disease lasting 16, 19 and 76 weeks.

Original languageEnglish
Pages (from-to)55-62
Number of pages8
JournalInvestigational New Drugs
Volume13
Issue number1
StatePublished - Jan 1 1995
Externally publishedYes

Fingerprint

Pentosan Sulfuric Polyester
Heparinoids
Partial Thromboplastin Time
Transaminases
Thrombocytopenia
Anticoagulants
Neoplasms

Keywords

  • Adult solid tumors
  • Pentosan polysulfate
  • Phase I trial

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Swain, S. M., Parker, B., Wellstein, A., Lippman, M. E., Steakley, C., & DeLap, R. (1995). Phase I trial of pentosan polysulfate. Investigational New Drugs, 13(1), 55-62.

Phase I trial of pentosan polysulfate. / Swain, S. M.; Parker, B.; Wellstein, A.; Lippman, Marc E; Steakley, C.; DeLap, R.

In: Investigational New Drugs, Vol. 13, No. 1, 01.01.1995, p. 55-62.

Research output: Contribution to journalArticle

Swain, SM, Parker, B, Wellstein, A, Lippman, ME, Steakley, C & DeLap, R 1995, 'Phase I trial of pentosan polysulfate', Investigational New Drugs, vol. 13, no. 1, pp. 55-62.
Swain SM, Parker B, Wellstein A, Lippman ME, Steakley C, DeLap R. Phase I trial of pentosan polysulfate. Investigational New Drugs. 1995 Jan 1;13(1):55-62.
Swain, S. M. ; Parker, B. ; Wellstein, A. ; Lippman, Marc E ; Steakley, C. ; DeLap, R. / Phase I trial of pentosan polysulfate. In: Investigational New Drugs. 1995 ; Vol. 13, No. 1. pp. 55-62.
@article{13c03a1fd67e4420ac065b21cdc8c148,
title = "Phase I trial of pentosan polysulfate",
abstract = "Pentosan polysulfate is a semisynthetic pentasaccharide heparinoid derived from beechwood shavings. A total of nineteen patients with various adult solid tumors were treated with three dose levels (15, 22.5, and 30 mg/m2/dose) of subcutaneous pentosan polysulfate every 6 hours. The dose limiting toxicities were thrombocytopenia and elevated transaminases at the dose of 30 mg/m2 every 6 hours. The recommended starting dose for phase II trials is 22.5 mg/m2 given every 6 hours. There was an increase in anticoagulant activity as measured by activated partial thromboplastin time (aPTT) at the dose of 22.5 mg/m2 every 6 hours in most patients. There were no objective responses and three patients had stable disease lasting 16, 19 and 76 weeks.",
keywords = "Adult solid tumors, Pentosan polysulfate, Phase I trial",
author = "Swain, {S. M.} and B. Parker and A. Wellstein and Lippman, {Marc E} and C. Steakley and R. DeLap",
year = "1995",
month = "1",
day = "1",
language = "English",
volume = "13",
pages = "55--62",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Phase I trial of pentosan polysulfate

AU - Swain, S. M.

AU - Parker, B.

AU - Wellstein, A.

AU - Lippman, Marc E

AU - Steakley, C.

AU - DeLap, R.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Pentosan polysulfate is a semisynthetic pentasaccharide heparinoid derived from beechwood shavings. A total of nineteen patients with various adult solid tumors were treated with three dose levels (15, 22.5, and 30 mg/m2/dose) of subcutaneous pentosan polysulfate every 6 hours. The dose limiting toxicities were thrombocytopenia and elevated transaminases at the dose of 30 mg/m2 every 6 hours. The recommended starting dose for phase II trials is 22.5 mg/m2 given every 6 hours. There was an increase in anticoagulant activity as measured by activated partial thromboplastin time (aPTT) at the dose of 22.5 mg/m2 every 6 hours in most patients. There were no objective responses and three patients had stable disease lasting 16, 19 and 76 weeks.

AB - Pentosan polysulfate is a semisynthetic pentasaccharide heparinoid derived from beechwood shavings. A total of nineteen patients with various adult solid tumors were treated with three dose levels (15, 22.5, and 30 mg/m2/dose) of subcutaneous pentosan polysulfate every 6 hours. The dose limiting toxicities were thrombocytopenia and elevated transaminases at the dose of 30 mg/m2 every 6 hours. The recommended starting dose for phase II trials is 22.5 mg/m2 given every 6 hours. There was an increase in anticoagulant activity as measured by activated partial thromboplastin time (aPTT) at the dose of 22.5 mg/m2 every 6 hours in most patients. There were no objective responses and three patients had stable disease lasting 16, 19 and 76 weeks.

KW - Adult solid tumors

KW - Pentosan polysulfate

KW - Phase I trial

UR - http://www.scopus.com/inward/record.url?scp=0029150566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029150566&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 55

EP - 62

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -